(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 89.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.58%.
Syndax Pharmaceuticals's revenue in 2026 is $111,551,000.On average, 16 Wall Street analysts forecast SNDX's revenue for 2026 to be $31,848,204,088, with the lowest SNDX revenue forecast at $20,101,663,733, and the highest SNDX revenue forecast at $41,332,351,211. On average, 14 Wall Street analysts forecast SNDX's revenue for 2027 to be $48,774,868,789, with the lowest SNDX revenue forecast at $25,467,785,831, and the highest SNDX revenue forecast at $83,047,127,709.
In 2028, SNDX is forecast to generate $65,611,142,058 in revenue, with the lowest revenue forecast at $49,760,483,052 and the highest revenue forecast at $80,737,800,463.